Literature DB >> 3288138

Important risk factors of allograft survival in cadaveric renal transplantation. A study of 426 patients.

A G Diethelm1, E H Blackstone, D C Naftel, S L Hudson, W H Barber, M H Deierhoi, B O Barger, J J Curtis, R G Luke.   

Abstract

Multiple risk factors contribute to the allograft survival of patients who have cadaveric renal transplantation. A retrospective review of 19 such factors in 426 patients identified race, DR match, B + DR match, number of transplants, and preservation time to have a significant influence. The parametric analysis confirmed the effect to be primarily in the early phase, i.e., first 6 months. All patients received cyclosporine with other methods of immunosuppression resulting in an overall 1-year graft survival rate of 66%. The overall 1-year graft survival rate in the white race was 73% and in the black race was 57% (p = 0.002). Allograft survival and DR match showed white recipients with a 1 DR match to have 75% survival at 1 year compared with 57% in the black patient (p = 0.009). If HLA B + DR match was considered, the white recipient allograft survival increased to 76%, 84%, and 88% for 1, 2, and 3 match kidneys by parametric analysis. Patients receiving first grafts had better graft survival (68%) than those undergoing retransplantation (58%) (p = 0.05). Organ preservation less than 12 hours influenced allograft survival with a 78% 1-year survival rate compared with 63% for kidneys with 12-18 hours of preservation. Despite the benefits of B + DR typing, short preservation time, and first transplants to the white recipient, the allograft survival in the black recipient remained uninfluenced by these parameters.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3288138      PMCID: PMC1493502          DOI: 10.1097/00000658-198805000-00008

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  12 in total

1.  A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES.

Authors:  E A GEHAN
Journal:  Biometrika       Date:  1965-06       Impact factor: 2.445

2.  Outcome of renal transplantation in blacks.

Authors:  H J Ward; M A Koyle; P I Terasaki; J M Cecka
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

3.  Influence of race on kidney transplant survival.

Authors:  G Opelz; M R Mickey; P I Terasaki
Journal:  Transplant Proc       Date:  1977-03       Impact factor: 1.066

4.  Correlation of HLA matching with kidney graft survival in patients with or without cyclosporine treatment.

Authors:  G Opelz
Journal:  Transplantation       Date:  1985-09       Impact factor: 4.939

5.  Cyclosporin in cadaveric renal transplantation: 3-year follow-up of a European multicentre trial.

Authors:  R Y Calne; A J Wood
Journal:  Lancet       Date:  1985-09-07       Impact factor: 79.321

6.  A 2-year trial of prospective HLA-DR matching: effects on renal allograft survival and rate of transplantation.

Authors:  N E Goeken; J S Thompson; R J Corry
Journal:  Transplantation       Date:  1981-12       Impact factor: 4.939

7.  Multivariate analysis of risk factors in cadaver donor kidney transplantation.

Authors:  F Sanfilippo; W K Vaughn; W M LeFor; E K Spees
Journal:  Transplantation       Date:  1986-07       Impact factor: 4.939

8.  The effect of zero HLA class I and II mismatching in cyclosporine-treated kidney transplant patients.

Authors:  J Cicciarelli; P I Terasaki; M R Mickey
Journal:  Transplantation       Date:  1987-05       Impact factor: 4.939

9.  Multivariate analysis of risk factors impacting on immediate and eventual cadaver allograft survival in cyclosporine-treated recipients.

Authors:  B D Kahan; R Mickey; S M Flechner; M I Lorber; C A Wideman; R H Kerman; P Terasaki; C T Van Buren
Journal:  Transplantation       Date:  1987-01       Impact factor: 4.939

10.  Influence of race on renal allograft survival in the pre- and postcyclosporine era.

Authors:  B O Barger; S L Hudson; T W Shroyer; M H Deierhoi; W H Barber; J J Curtis; B A Julian; R G Luke; A G Diethelm
Journal:  Clin Transpl       Date:  1987
View more
  7 in total

1.  The point system for organ distribution.

Authors:  T E Starzl; R Shapiro; L Teperman
Journal:  Transplant Proc       Date:  1989-06       Impact factor: 1.066

2.  Outcome after myocardial revascularization and renal transplantation: a 25-year single-institution experience.

Authors:  E R Ferguson; S L Hudson; A G Diethelm; A D Pacifico; L S Dean; W L Holman
Journal:  Ann Surg       Date:  1999-08       Impact factor: 12.969

3.  Overall Graft Loss Versus Death-Censored Graft Loss: Unmasking the Magnitude of Racial Disparities in Outcomes Among US Kidney Transplant Recipients.

Authors:  David J Taber; Mulugeta Gebregziabher; Elizabeth H Payne; Titte Srinivas; Prabhakar K Baliga; Leonard E Egede
Journal:  Transplantation       Date:  2017-02       Impact factor: 4.939

4.  Renal transplantation in black recipients at the University of Pittsburgh.

Authors:  R Shapiro; A G Tzakis; T R Hakala; W B Lopatin; A C Stieber; T E Starzl
Journal:  Transplant Proc       Date:  1989-12       Impact factor: 1.066

5.  Ten-year experience with cyclosporine as primary immunosuppression in recipients of renal allografts.

Authors:  N L Tilney; A Chang; E L Milford; W D Whitley; J M Lazarus; E L Ramos; T B Strom; C B Carpenter; R L Kirkman
Journal:  Ann Surg       Date:  1991-07       Impact factor: 12.969

6.  Benefits of quadruple immunosuppressive therapy in recipients of living related donor kidneys. A review of 855 operations.

Authors:  A G Diethelm; D A Laskow; S L Hudson; M H Deierhoi; W H Barber; B O Barger; B A Julian; R S Gaston; J J Curtis
Journal:  Ann Surg       Date:  1992-06       Impact factor: 12.969

7.  Amelioration of renal damage by administration of anti-thymocyte globulin to potential donors in a brain death rat model.

Authors:  F Cicora; P Stringa; D Guerrieri; J Roberti; N Ambrosi; F Toniolo; P Cicora; G Palti; D Vásquez; C Raimondi
Journal:  Clin Exp Immunol       Date:  2012-09       Impact factor: 4.330

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.